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(CABG).1 A transcardiac production of inflammatory
substances has also been shown in patients treated with
percutaneous transluminal coronary angioplasty
(PTCA) for myocardial infarction.2
In experimental studies nitric oxide (NO) has been
shown to reduce reperfusion injury. The concomitant
cardioprotective effect of sodium nitroprusside (SNP)
under experimental conditions was interpreted to result
from radical scavenging by NO.3,4 In a clinical study in
pediatric patients undergoing cardiac operations for
congenital malformations, a reduction of complement
activation during cardiopulmonary bypass (CPB) was
observed with SNP.5 This was responsible for the
diminished rise in inflammatory parameters noted by
the authors. In patients with normal left ventricular
function undergoing elective CABG, short-term (20
minutes) application of the NO donor SNP during
T he human heart has been shown to be a site ofinflammation during postischemic reperfusion in
patients undergoing coronary artery bypass grafting
Objective: The aim of the present study was to investigate whether the
nitric oxide donor sodium nitroprusside can reduce the cardiac inflam-
matory response during coronary artery bypass grafting in patients
with severely compromised left ventricular function. Methods: Patients
(n = 30) were assigned to receive placebo or sodium nitroprusside (0.5
µg · kg–1 · min–1) for the first 60 minutes of reperfusion. Interleukin 6,
interleukin 8, and tumor necrosis factor α levels; platelet adhesion mol-
ecule CD41 and CD62 levels; and CD11b on leukocytes were determined
in the radial artery and coronary sinus before cardiopulmonary bypass
and during reperfusion (1, 5, 10, 35, and 75 minutes). Results: At 1
minute of reperfusion, coronary venous levels of CD41-positive poly-
morphonuclear leukocytes were 8% lower than arterial levels in the
placebo group and 18% higher in the sodium nitroprusside group (P =
.021). At 5 minutes of reperfusion, the respective levels were 29% and
1% for interleukin 6 (P = .015), –5% and 20% for CD41-positive mono-
cytes (P = .032), and –2% and 16% for CD11b-positive monocytes (P =
.038). At 10 minutes of reperfusion, these levels were –14% and 21% for
CD41-positive monocytes (P = .006). At 35 minutes of reperfusion, these
levels were –13% and 7% for CD41-positive monocytes (P = .017), –41%
and 23% for CD11b-positive monocytes (P = .001), and 7% and 25% for
CD62-positive platelets (P = .041). At 75 minutes of reperfusion, the lev-
els were 15% and –7% for tumor necrosis factor α (P = .025) and –10%
and 10% for CD62-positive platelets (P = .041). Conclusions: Trans-
cardiac production of proinflammatory cytokines is reduced in patients
undergoing coronary artery bypass grafting treated with the nitric
oxide donor sodium nitroprusside. At the same time, less activated
leukocytes and platelets are retained in the coronary circulation. (J
Thorac Cardiovasc Surg 2000;119:566-74)
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postischemic reperfusion was able to reduce the sys-
temic inflammatory response reaction and also the trans-
cardiac production of inflammatory mediators.6 A neg-
ative inotropic potential of cytokines has been
described.7 Therefore the present study was performed
in patients with severely compromised left ventricular
function undergoing CABG to investigate whether the
administration of SNP could mitigate the inflammatory
response of the heart to CPB and ischemia-reperfusion
and at the same time lead to less need for cate-
cholamines after termination of CPB. Parameters mea-
sured included the proinflammatory cytokines inter-
leukin 6 (IL-6), IL-8, and tumor necrosis factor α
(TNF-α); leukocyte adhesion molecule CD11b; and
platelet adhesion molecules CD41 and CD62.
Patients and methods
Anesthesia. Anesthesia was conducted as a total intra-
venous technique. Induction of anesthesia was performed
with 1 µg/kg sufentanil, 0.04 mg/kg midazolam, and 0.1
mg/kg pancuronium. A loading dose of 3 µg/kg sufentanil
and 0.1 mg/kg midazolam was given before sternotomy.
Thereafter the infusion was adjusted to 0.5 µg · kg–1 · h–1
sufentanil and 0.03 mg · kg–1 · h–1 midazolam and maintained
until the end of the operation. Dopamine (3 µg · kg–1 · min–1)
was used throughout the procedure to maintain adequate
urine output. Before separation from CPB, the infusion rate
was set according to the patient’s circulatory state. A cardiac
index of at least 2.3 L · min–1 · m–2 and a mean arterial pres-
sure of at least 60 mm Hg were the targets. Aprotinin
(Trasylol; Bayer, Leverkusen, Germany) was given according
to the Hammersmith protocol (total dose 6 million KIU).
Operation and intervention. All patients underwent
CABG with CPB by using roller pumps (Stöckert, Munich,
Germany) and disposable membrane oxygenators (Dideco,
Mirandola, Italy). The pump was primed with 1500 mL of
lactated Ringer solution to which 100 mmol of sodium bicar-
bonate and 5000 IU of heparin (Ratiopharm, Ulm, Germany)
were added. CPB was instituted at a flow rate of 2.4 L · min–1
·m–2 body surface area after systemic heparinization (1
mg/kg). After the application of heparin, an activated clotting
time of greater than 400 seconds was the target. When apro-
tinin was added, the target became 700 seconds. The body
temperature was cooled to 26°C to 28°C (moderate hypother-
mia), and 1000 mL of cold Bretschneider solution (Custodiol;
Köhler Chemie, Alsbach-Hähnlein, Germany) was applied as
antegrade cardioplegia after clamping of the aorta. The
remaining blood of the CPB circuit was prepared by using a
Cell-Saver device (Haemonetics, Munich, Germany) before
retransfusion.
After release of the aortic crossclamp, patients received
either 5% glucose solution (the solvent for Nipruss) as place-
bo or SNP (Nipruss 0.5 µg · kg–1 · min–1), both of which were
infused through the central venous line of a Swan-Ganz
catheter (Baxter Healthcare Corp, Edwards Division, Santa
Ana, Calif). The dose was chosen according to pre-experi-
ments, in which 0.5 µg · kg–1 · min–1 was the highest dose that
showed no significant hemodynamic effects. The infusion
was stopped after 60 minutes. Protamine (1 mg/kg) was given
after CPB.
The use of cardiotomy suction was reduced to a minimum
while proximal anastomoses were completed. Cardiotomy
suction was not used after termination of CPB.
Blood samples. The blood for arterial measurements was
drawn from a cannula in the radial artery. The coronary
venous blood was withdrawn from a catheter (multipurpose,
6F; Cordis; Roden, The Netherlands), which was transcuta-
neously placed into the coronary sinus through the internal
jugular vein under fluoroscopic control. The correct position
of this catheter was monitored by registering the pressure
curve and determining oxygen saturation (25%-45%) of sam-
ples from coronary sinus blood. Samples were taken at the
following time points: (1) after application of heparin; (2) 1,
Table I. Preoperative and intraoperative patient data
Placebo SNP P value
Patient age (y) 63 ± 7 67 ± 6 .05
Patient sex 3 women, 12 men 4 women, 11 men >.2
Ejection fraction (%) 33 ± 10.2 37 ± 8.7 .06
Myocardial infarction 1.1 ± 0.7 0.9 ± 0.5 .2
NYHA class 2.4 ± 0.5 2.4 ± 0.5 >.2
Blood pressure at beginning of reperfusion (mm Hg) 61 ± 10 56 ± 14 .2
Decrease of blood pressure during reperfusion (mm Hg) 24 ± 11 24 ± 10 >.2
Duration of ischemia (min) 65 ± 13 68 ± 12 >.2
Duration of reperfusion (min) 34 ± 9 31 ± 9 >.2
No. of distal anastomoses 3.4 ± 0.7 3.5 ± 0.8 >.2
No. of proximal anastomoses 1.9 ± 0.7 1.9 ± 0.5 >.2
Dopamine after termination of CPB (µg · kg–1 · min–1) 5.4 ± 2.2 5.7 ± 1.8 >.2
Dobutamine after termination of CPB (µg · kg–1 · min–1) 1.2 ± 2.8 1.7 ± 2.4 >.2
Patients requiring norepinephrine after CPB 2/15 3/15 >.2
Values are means ± SD (n = 15 patients each). The Z test was used for statistical comparison of patient sex and of patients requiring norepinephrine after CPB. NYHA,
New York Heart Association.
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5, and 10 minutes after release of the aortic crossclamp; (3)
after termination of CPB (approximately 35 minutes after
release of the aortic crossclamp), and (4) 75 minutes after
release of the aortic crossclamp. Blood was simultaneously
drawn from the radial artery and the coronary sinus at all time
points.
Patients. The study was performed in a prospective and
double-blind fashion. Inclusion criteria were as follows: (1) a
left ventricular ejection fraction of 40% or less, (2) age of 80
years or less, and (3) no myocardial infarction (as defined by
significant elevation of serum creatine kinase levels and/or
electrocardiographic signs for myocardial infarction) within
14 days before the operation.
Exclusion criteria were known hypersensitivity against
SNP or any other nitro substances, inflammatory diseases, or
the intake of immunosuppressive drugs. A further exclusion
criterion was unstable angina. Only patients undergoing elec-
tive CABG were enrolled.
Every patient with a profile suitable for enrollment in the
study was informed about the nature of the study and about
potential side effects of the application of SNP and was
required to sign a written consent form 1 day before the oper-
ation. The preoperative patient characteristics are shown in
Table I. The study was approved by the local ethics commit-
tee in August 1996. SNP (Nipruss) was donated by Schwarz
Pharma (Monheim, Germany). The investigation conforms
with the principles outlined in the Declaration of Helsinki.
From November 1997 until December 1998, 58 patients
were elected to take part in the study and had signed the con-
sent form. However, 28 patients had to be excluded because
the coronary sinus catheter, which was placed in the operat-
ing room, could not be positioned in the right place within the
time limit set for this procedure (15 minutes).
Immunoassays. For analysis of cytokines and cell counts,
blood specimens were collected into heparinized tubes
(Sarstedt, Nümbrecht, Germany). Plasma samples were
stored frozen at –20°C until assayed within batches. IL-6, IL-
8, and TNF-α levels were measured by using a solid-phase,
2-site, chemiluminescent enzyme immunometric assay
(Immulite system; Diagnostic Products Corporation, Los
Angeles, Calif). Cardiac release of IL-6, IL-8, and TNF-α
was calculated from the respective coronary venoarterial dif-
ferences at each time point.
Flow cytometry. Flow cytometry of adhesion molecules
on platelets and leukocytes was performed as previously
described.1 In brief, for determination of leukocyte adhesion
molecules, aliquots of the blood samples were mixed with 1
mL of FACS lysing solution (Becton Dickinson, Heidelberg,
Germany) and double stained with anti-CD41 antibodies
(Serotec, Kidlington, Oxford, Great Britain) and anti-CD11b
antibodies (Exalpha, Boston, Mass). For analysis of platelets,
100 µL of blood and 1 mL of Cellfix (Becton Dickinson)
were mixed and incubated with antibodies against CD41
(Serotec) and CD62 (Harlan Seralab, Crawley Down, Sussex,
Great Britain).
Flow cytometry was performed with a FACScan and Lysis
II software (Becton Dickinson). The mean fluorescence
intensity was taken as a measure of antibody binding. The
nonspecific background was quantified by measurement of
the fluorescence intensity of samples labeled with nonbind-
Table II. Radial artery values for the cytokines IL-6, IL-8, and TNF-α, as well as the adhesion molecules CD11b
on monocytes and PMNs, CD41 and CD62 on platelets, and CD41 on monocytes and PMNs
Pre-CPB 1 min 5 min 10 min 35 min 75 min
Placebo
IL-6 (pg/mL) 15.9 ± 5.3 85.7 ± 12.2 140.3 ± 20.7 133.4 ± 20.7 320.3 ± 46.3 248.0 ± 85.2
IL-8 (pg/mL) 6.0 ± 0.4 11.8 ± 1.2 12.0 ± 1.1 12.6 ± 1.3 21.4 ± 2.3 28.3 ± 7.6
TNF-α (pg/mL) 9.3 ± 0.8 11.3 ± 1.1 11.6 ± 1.0 12.0 ± 0.8 14.0 ± 1.5 25.4 ± 9.4
CD11b monocytes (fluorescence units) 16.1 ± 4.1 17.9 ± 2.8 18.6 ± 2.9 16.5 ± 2.5 17.3 ± 3.9 11.8 ± 1.8
CD11b PMNs (fluorescence units) 15.1 ± 4.4 13.6 ± 2.6 14.8 ± 3.4 12.5 ± 2.2 13.2 ± 3.5 12.2 ± 2.2
CD41 platelets (fluorescence units) 94.5 ± 10.9 125.8 ± 14.0 129.8 ± 13.8 132.3 ± 13.2 120.5 ± 13.6 136.7 ± 12.9
CD62 platelets (fluorescence units) 8.3 ± 1.8 12.6 ± 2.8 12.7 ± 2.9 13.2 ± 2.9 12.8 ± 2.8 15.7 ± 2.7
CD41 monocytes (% positive) 31.3 ± 3.3 43.5 ± 5.7 48.2 ± 5.5 45.2 ± 5.6 40.9 ± 6.5 37.6 ± 5.1
CD41 PMNs (% positive) 23.5 ± 2.5 23.1 ± 2.9 22.5 ± 2.3 20.7 ± 2.3 20.0 ± 2.7 19.2 ± 2.4
SNP
IL-6 (pg/mL) 12.9 ± 2.7 49.8 ± 9.4 87.2 ± 17.1 105.8 ± 20.3 240.2 ± 44.1 340.9 ± 46.6
IL-8 (pg/mL) 7.0 ± 1.1 17.9 ± 4.7 18.3 ± 4.4 19.3 ± 4.2 32.2 ± 5.8* 33.6 ± 6.6
TNF-α (pg/mL) 9.3 ± 1.7 11.9 ± 1.9 12.2 ± 1.7 12.6 ± 1.9 16.9 ± 2.8 29.9 ± 7.6
CD11b monocytes (fluorescence units) 13.8 ± 1.4 17.3 ± 2.5 19.2 ± 3.9 17.1 ± 2.7 15.2 ± 2.4 15.1 ± 1.9
CD11b PMNs (fluorescence units) 12.9 ± 1.4 15.8 ± 2.3 19.7 ± 5.1 15.9 ± 3.2 12.6 ± 1.4 14.8 ± 2.3
CD41 platelets (fluorescence units) 87.0 ± 9.8 117.9 ± 12.5 119.5 ± 11.9 115.9 ± 12.1 109.5 ± 10.3 121.2 ± 12.4
CD62 platelets (fluorescence units) 10.0 ± 1.9 14.0 ± 2.6 15.4 ± 2.5 15.0 ± 2.5 14.4 ± 2.4 16.5 ± 2.6
CD41 monocytes (% positive) 37.8 ± 4.4 48.4 ± 4.0 46.5 ± 3.7 46.3 ± 3.4 44.6 ± 3.3 42.3 ± 3.2
CD41 PMNs (% positive) 26.0 ± 2.5 28.0 ± 3.0 24.9 ± 2.2 23.5 ± 2.4 23.3 ± 2.4 22.2 ± 2.8
Values are means ± SEM. The columns indicate time points of blood sampling before CPB followed by 5 time points during reperfusion (n = 15 patients each).
*P = .046 versus placebo.
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ing isotype-matched antibodies and subsequently subtracted.
Results are given in the percentage increase or decrease of a
parameter in the coronary venous sample compared with the
respective arterial sample. This normalization was necessary
because of the considerable scatter of the baseline levels of
the individual patients.
Statistical analysis. All results are expressed as mean val-
ues ± SEM. The Student t test for paired samples was used to
evaluate differences between the groups.
Results
Interleukins and adhesion molecules. Arterial val-
ues for the cytokines IL-6, IL-8, and TNF-α, as well as
the adhesion molecules CD11b on monocytes and
polymorphonuclear leukocytes (PMNs), adhesion mol-
ecules CD41 and CD62 on platelets, and CD41 on
monocytes and PMNs are shown in Table II. The arter-
ial values are similar between the groups, with the
exception of the IL-8 levels after termination of CPB.
Here a higher value was measured in the SNP group,
which cannot be readily explained.
In the case of the cytokines, there was a general trend
toward lower concentrations in the coronary sinus.
Coronary venoarterial differences of IL-6 and TNF-α
levels are shown in Figs 1 and 2 as percentage values
because of interindividual scatter. In contrast to the
placebo group, the transmyocardial difference for IL-6
in the SNP group remained near zero at all time points
after the first-minute reperfusion.
Coronary venoarterial differences for TNF-α were
similar in both groups in early reperfusion. However, in
contrast to the SNP group, after 75 minutes of reperfu-
sion, a production of TNF-α was observed in the place-
bo group (Fig 2).
The application of SNP exerted no significant effects
on coronary venoarterial differences of IL-8.
The general trend in the transcardiac differences of
activated leukocytes and platelets was toward a reten-
tion in the placebo group and toward a washout in the
SNP group. This was observed in the case of CD11b-
positive monocytes at 1 and 30 minutes of reperfusion
(Fig 3).
No significant differences in transcardiac gradients of
CD11b expression on PMNs or CD41 expression on
platelets were observed at any time point.
Figs 4 and 5 show the coronary venoarterial differ-
ences for the expression of the platelet adhesion mole-
cule CD41 on monocytes and PMNs, respectively. The
above-mentioned trend was again present, with a
washout of CD41-positive monocytes occurring in the
SNP group and a retention in the placebo group (Figs 4
and 5).
The same general direction was present in the case of
CD62-positive platelets (Fig 6).
Clinical characteristics. All 30 patients survived.
Preoperative, intraoperative, and postoperative charac-
teristics are shown in Table I. Decline in blood pressure
was equal in patients receiving placebo and those
receiving SNP. No significant differences could be
observed concerning the intraoperative characteristics
or the need for catecholamines (dopamine, dobuta-
mine, and norepinephrine) after termination of CPB.
There was no low output syndrome in either group and
no need to use an intra-aortic balloon pump in any of
the patients. Postoperative myocardial infarction was
diagnosed when significant ST-segment elevation was
present in the electrocardiogram and significant
myocardial enzyme increase was determined (myocar-
dial fraction of creatine kinase greater than 10% of sys-
temic levels). In 2 of 15 patients receiving placebo,
temporary ST-segment elevation was noted without
significant myocardial creatine kinase levels. The same
nonspecific changes were observed in 1 of 15 patients
receiving SNP. The highest creatine kinase level in the
placebo group was 899 IU/L, with a myocardial frac-
tion of 25 IU/L. This patient did not have electrocar-
diographic abnormalities. The highest creatine kinase
level in the SNP group was 1080 IL/L, with a myocar-
dial fraction of 21 IU/L. No electrocardiographic
abnormalities were observed.
Discussion
In the present study the application of SNP to
patients undergoing CABG with compromised left
ventricular function for the first 60 minutes of reperfu-
sion led to a reduction of the acute cardiac inflamma-
tory response. In addition to diminished cardiac pro-
duction of IL-6 and TNF-α, a washout of
platelet-bearing leukocytes and of activated platelets,
as well as of activated leukocytes during coronary pas-
sage, was observed in SNP-treated patients.
The effect was achieved without inducing systemic
hemodynamic changes with SNP that outranged those
occurring in the placebo group. Theoretically, coronary
vascular resistance and flow rate, which were not mea-
sured in this study, could have been altered by low-dose
SNP. However, in the presence of pre-existing ischemic
vasodilation, such an effect seems rather unlikely.
Interleukins and adhesion molecules. Cardiac
cytokine release has been shown during recanalization
by means of PTCA in acute myocardial infarction,
along with a significant cardiac production of IL-6 dur-
ing reperfusion of the heart undergoing infarction,2 in a
previous study in patients undergoing CABG with nor-
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mal left ventricular function6 and again in the present
study. In patients undergoing PTCA without myocar-
dial infarction, no such cytokine release was observed.2
Thus the cardiac production of cytokines seems to be a
phenomenon occurring in cases of severe ischemia and
reperfusion.
In the present work the significant production of IL-
6 observed in control patients during early reperfusion
Fig 1. Coronary venoarterial difference of IL-6 levels, with the respective arterial value taken as 100%. Values
are means, and bars represent SEM (n = 15 for each group; filled circles, placebo group patients; filled squares,
SNP group patients). When differences between groups were significant, the respective levels are written on top
of the symbols.
Fig 2. Coronary venoarterial difference of TNF-α levels, with the respective arterial value taken as 100%. Values
are means, and bars represent SEM (n = 15 for each group; filled circles, placebo group patients; filled squares,
SNP group patients). When differences between groups were significant, the respective levels are written on top
of the symbols.
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was mitigated by SNP. TNF-α release into coronary
venous blood was greatest after 75 minutes of reperfu-
sion in patients receiving placebo and was prevented in
SNP-treated patients. The overall relatively small pro-
duction of TNF-α observed here may well be due to the
routine application of aprotinin.8 Cytokines have been
reported to exert negative inotropic effects.7 The miti-
gation of such an influence might have been particular-
ly beneficial in patients with compromised left ventric-
ular function, as studied here. However, as the data on
inotropic support show, there was no benefit with
respect to the need for catecholamines under the appli-
cation of SNP. In both groups the early postoperative
course was relatively uneventful (no intra-aortic bal-
loon pump and no low output syndrome), and therefore
a potential functional benefit within this time period
might have been obscured.
On the basis of actual cell counts, performed in a pre-
vious study of our group,1 the appearance of more acti-
vated leukocytes and platelets in the coronary venous
blood indicates their washout, whereas a decline of
activated cells is a sign of their retention in the coro-
nary bed. Retained and activated leukocytes may be
responsible for the release of cytokines.9 In recent stud-
ies on the inflammatory response of the lungs of
patients undergoing CABG, significant cellular reten-
tion and subsequent cytokine release were demonstrat-
ed.10,11 Retention is an indicator for interaction
between the endothelium and the respective cells. The
endothelium is activated during reperfusion,1 thus mak-
ing the retention of activated cells more probable. The
diminished retention and even washout in the case of
SNP-treated patients observed in the present study may
be interpreted as being cardioprotective because the
related sequelae, such as chemotactic activation, trans-
migration, and burst reaction, may be prevented.
Marked activation of platelets during CPB has been
described.12 The retention of activated platelets during
coronary passage is a risk factor for restenosis.13 In the
present study the influence of SNP on the interaction of
activated platelets and the coronary endothelium led to
a washout instead of retention of CD62-positive (P-
selectin) platelets in patients receiving SNP. Activated
blood platelets express the adhesion molecule CD41
(GpIIb/IIIa) on the membrane surface. This molecule
(among others) allows platelets to coaggregate with the
larger leukocytes, especially monocytes and PMNs.
Again, washout of CD41-positive monocytes and
PMNs in the present study indicates less interaction
between the coronary vascular endothelium and
platelet-leukocyte coaggregates under the application
of SNP.
Surprisingly, no effects on the transmyocardial dif-
ference of quantitative cell counts were observed,
Fig 3. Coronary venoarterial difference of CD11b-positive monocytes, with the respective arterial value taken as
100%. Symbols are means, and bars represent SEM (n = 15 for each group; filled circles, placebo group patients;
filled squares, SNP group patients). When differences between groups were significant, the respective levels are
written on top of the symbols.
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which is in contrast to the pulmonary data in patients
undergoing CABG, in whom significant quantitative
cellular retention is observed.10
Timing of intervention and the involved mecha-
nism. The optimal timing of intervention with a donor
of NO is unclear in the literature. Inhibition of the pro-
duction of endogenous NO was found to be greatest
starting with postischemic reperfusion.14 On the other
hand, it was reported that recovery of the reperfused
heart was greatest when NO was supplemented before
Fig 4. Coronary venoarterial difference of CD41-positive monocytes, with the respective arterial value taken as
100%. Values are means, and bars represent SEM (n = 15 each group; filled circles, placebo group patients; filled
squares, SNP group patients). When differences between groups were significant, the respective levels are writ-
ten on top of the symbols.
Fig 5. Coronary venoarterial difference of CD41-positive PMNs, with the respective arterial value taken as 100%.
Values are means, and bars represent SEM (n = 15 for each group; filled circles, placebo group patients; filled
squares, SNP group patients). When differences between groups were significant, the respective levels are writ-
ten on top of the symbols.
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cardioplegia and that the application during reperfusion
may even be detrimental.15 In our own experience, on
the basis of animal studies, the best results were
obtained with the short-term postischemic application
of an NO donor.3 In the present study the duration of
application was chosen to be 60 minutes instead of 20
minutes, as in a previous study.6 The reason was to pro-
long the previously observed anti-inflammatory effects.
In patients with normal left ventricular function inves-
tigated in the previous study, the influence of SNP on
the transcardiac production of cytokines and on the
retention of activated leukocytes and platelets had, in
fact, been weaker.6 However, the results of the 2 stud-
ies can only be compared with caution because (1) bub-
ble oxygenators were used in the previous study and
membrane oxygenators were used in the present study
and (2) the administration of SNP was prolonged from
20 to 60 minutes.
On the one hand, free radical generation has been
reported to be more pronounced16 and extravascular
lung water has been reported to be increased17 in the
case of bubble oxygenators. On the other hand, a large
prospective study found no difference in duration of
ventilation, intrapulmonary shunting, or hospital mor-
tality rates between patients undergoing operations
with bubble oxygenators and those undergoing opera-
tions with membrane oxygenators.18
An inhibiting effect on systemic complement activa-
tion by SNP infusion was observed in a study per-
formed in children undergoing cardiac operations for
congenital malformations.5 Complement activation
was not measured in the present study but could occur
subsequent to endothelial, leukocyte, and platelet acti-
vation. A radical scavenger effect of NO has been sug-
gested from experimental studies.3,4 Although NO is
known to be liberated from SNP, the exact mechanism
of action in the present study remains unclear.
Taken together, the 60-minute administration of SNP
used in the present study seemed to have a more pro-
nounced mitigating effect on the production of proin-
flammatory stimuli and on the interaction between acti-
vated blood cells and the endothelium than the
20-minute application used before.6 Considering that
different types of oxygenators were used, the fact that
preoperative left ventricular function was compromised
may have had a sensitizing influence. A number of
studies have shown anti-inflammatory effects for dif-
ferent agents. The physiologic significance of the
increased levels of proinflammatory substances in var-
ious situations of ischemia and reperfusion and their
reduction by anti-inflammatory agents remains to be
determined. Thus far, a functional benefit could not be
demonstrated by any of the interventions.
In conclusion, after declamping of the aorta in
patients undergoing CABG, SNP infusion reduces the
transcardiac release of several proinflammatory stim-
uli. This is accompanied by a washout of activated
leukocytes, platelets, and coaggregates of these 2 cell
Fig 6. Coronary venoarterial ratio of CD62-positive platelets, with the respective arterial value taken as 100%.
Values are means, and bars represent SEM (n = 15 for each group; filled circles, placebo group patients; filled
squares, SNP group patients). When differences between groups were significant, the respective levels are writ-
ten on top of the symbols.
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types. The latter indicates less interaction between the
coronary endothelium and the respective activated
cells, which should mitigate postoperative reperfusion
complications.
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